Emergent BioSolutions

Share Interview Share Compensation

$107M Part D

LOE Approaching

Company's sole revenue driver; approaching loss of exclusivity creates critical business vulnerability.

Help build intelligence for Emergent BioSolutions

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Specialized expertise in biodefense and vaccine development across a robust pipeline including anthrax, smallpox, cholera, and emerging infectious disease programs
CDMO platform positions you at the intersection of contract manufacturing and drug development, offering exposure to both operational and clinical advancement
Government contracting relationships (biodefense focus) provide revenue stability and long-term program visibility rare in commercial pharma

Watch Out For

Extreme revenue concentration: 100% dependency on SEROSTIM creates existential restructuring risk if the product faces generic competition or market loss
Pipeline is early-stage heavy (11 Phase 1 programs vs. only 1 Phase 3) with limited near-term catalysts; most programs target niche indications (anthrax, botulism, cholera) with modest commercial upside
Only 1 active job opening reported; minimal hiring suggests either stability or stagnation—difficult to assess growth trajectory

Generated by Claude from Emergent BioSolutions's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SAIZEN

Smallpox-related infections

$122K Part D

LOE Approaching

Minimal revenue contributor; approaching LOE alongside SEROSTIM.

TEMBEXA

Peak8.0yr

Biodefense-focused therapy with patent protection extending to 2034; potential niche revenue stream.

SEROSTIM LQ

LOE Approaching

Line extension of lead product; LOE trajectory mirrors core SEROSTIM.

NARCAN

Opioid overdose reversal

Peak

Established opioid crisis intervention therapy; stable revenue potential.

ACCRETROPIN

LOE Approaching

Additional somatropin formulation; portfolio exposure to shared GHD market erosion.

Pipeline & Clinical Trials

Collection of samples

Infections, Bacterial

N/A

ACAM2000® smallpox vaccine

Complication of Smallpox Vaccination

N/A

Clinical Trials (1)

NCT00927719Safety Surveillance Study of ACAM2000® Vaccinia Vaccine

N/A

BAT

Botulism

N/A

Clinical Trials (1)

NCT02055183BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin

N/A

AIGIV

Inhalational Anthrax

N/A

VIGIV

N/A

Clinical Trials (1)

NCT01374984VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection

N/A

Observational Intervention

Pregnancy Complications

N/A

Clinical Trials (1)

NCT01653392BioThrax® (Anthrax) Vaccine in Pregnancy Registry

N/A

Vivotif

Typhoid Fever

N/A

CYFENDUS

N/A

Clinical Trials (1)

NCT07268612Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.

N/A

Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

N/A

Clinical Trials (1)

NCT01540929Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

N/A

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

N/A

Clinical Trials (1)

NCT00928577Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

N/A

ACAM2000® Myopericarditis Registry

Myocarditis

N/A

Clinical Trials (1)

NCT01395082ACAM2000® Myopericarditis Registry

N/A

AIGIV

N/A

PXVX0047 Vaccine

Adenoviral Infection

Phase 1

Clinical Trials (1)

NCT03160339A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

Phase 1

16 mg naloxone AP003

Opioid Overdose

Phase 1

Clinical Trials (1)

NCT05377255Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

Phase 1

Brincidofovir

Phase 1

Clinical Trials (1)

NCT05935917Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

Phase 1

AERAS-402

Tuberculosis

Phase 1

Clinical Trials (1)

NCT01683773Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A

Phase 1

PXVX0200

Cholera

Phase 1

Botulinum Antitoxin Heptavalent

Healthy

Phase 1

VLA1601

Zika Virus

Phase 1

AVP-21D9

Bacillus Anthracis (Anthrax) Infection

Phase 1

Clinical Trials (1)

NCT01202695Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

Phase 1

UV-4B 30 mg oral solution

Viral Infection

Phase 1

Botulism Antitoxin Bivalent

Healthy Volunteers

Phase 1

AVA

Anthrax Infection

Phase 1

Clinical Trials (1)

NCT01979406A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

Phase 1

COVID-HIGIV

COVID-19

Phase 1

Clinical Trials (1)

NCT04661839A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

Phase 1

Placebo

Bird Flu

Phase 1

Clinical Trials (1)

NCT01006798Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Phase 1

UV-4B 3 mg

Viral Infection

Phase 1

Clinical Trials (1)

NCT02061358Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects

Phase 1

COVID-HIG

SARS-CoV-2 Infection

Phase 1

Clinical Trials (1)

NCT05142306A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults

Phase 1

UFluA 20 µg each antigen/dose

Human Influenza

Phase 1

Clinical Trials (1)

NCT05155319Universal Influenza A Vaccine in Healthy Adults

Phase 1

BioThrax

Phase 1

Ad4-mgag

Healthy Volunteer

Phase 1

Stabilized Isoamyl Nitrite

Cyanide Poisoning

Phase 1

Clinical Trials (1)

NCT05194358Study of SIAN Nasal Spray in Healthy Adults

Phase 1

NP-015

Symptoms of Inhalational Anthrax

Phase 1

Zika Virus Immune Globulin

Zika Virus Infection

Phase 1

Clinical Trials (1)

NCT03624946Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)

Phase 1

Ad4-mgag

Vaccine Response

Phase 1

AIGIV 3.5 mg/kg

Phase 1/2

Clinical Trials (1)

NCT00845650Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

Phase 1/2

FLU-IGIV

Influenza A H3N2

Phase 2

Clinical Trials (1)

NCT03315104Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Phase 2

BioThrax

Chikungunya Virus Infection

Phase 2

CHIKV VLP/unadjuvanted

Phase 2

CHIKV VLP, adjuvanted

Chikungunya Virus

Phase 2

AV7909

Phase 2

TRU-015

Arthritis, Rheumatoid

Phase 2

Ciprofloxacin 500Mg Tablet

Phase 2

Clinical Trials (1)

NCT04067011Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

Phase 2

Vaccinia virus: ACAM2000 smallpox vaccine

Phase 2

Clinical Trials (1)

NCT00053495Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Phase 2

Chikungunya

Phase 2

CHOP + CD4

T-cell Lymphoma

Phase 2

Clinical Trials (1)

NCT00893516CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

Phase 2

PXVX0200 10E8

Cholera

Phase 2

Clinical Trials (1)

NCT02145377PXVX0200 (CVD103-HgR) vs Shanchol in Mali

Phase 2

Dose of 5.0 x 10^9 CFU

Typhoid

Phase 2

Clinical Trials (1)

NCT00679172Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Phase 2

ACAM2000 Smallpox Vaccine